While treatment with native MAG-1 seems to be more effective on tumors derived from the classical cell line NCI H345 representing primary disease, it still has a significant effect on tumors derived from the variant cell line NCI H82, obtained from a pleural effusion and representing recurrent SCLC (39, 40). This evidence concerns the gene GPAT3 and small cell lung carcinoma.